Schizophrenia Treatment Innovations: App Submission for FDA Approval

Boehringer Ingelheim has announced plans to submit an app for FDA approval designed to treat symptoms of schizophrenia. Developed in collaboration with Click Therapeutics, the app, known as CT-155, is a 16-week treatment aimed at addressing under-treated negative symptoms of schizophrenia, which can include lack of motivation and an inability to experience pleasure.

The app is intended to be used alongside traditional antipsychotic medications. According to results from a late-stage clinical trial involving 464 participants, those using the app showed improvements in a rating scale for these symptoms compared to a control group using an alternative app.

Importantly, the treatment met its primary endpoint, achieving a prespecified threshold for effect size, indicating its potential effectiveness as a psychiatric treatment option.